Aditec, the great European project on vaccines presented at the European Parliament
The results of Aditec, the project launched in 2011, have been recently presented at the European Parliament. During a meeting of the highest representatives of the European Union involved in research and development, the project was extended to 2017, following discussion on the vaccine sector in Europe.
In less than six years, this project has allowed to develop novel immunization technologies, adjuvants, vectors and delivery systems, formulations and vaccination methods optimized for different age groups, 12 clinical trials and 207 scientific publications.
Aditec is a success story: with a 30 budget of million euro, bringing together 42 research institutions from 13 countries under an entirely Italian coordination, the project has established a new model for vaccine research, based on a strong synergy between private and public institutions that has proved to be most effective.
Paul Rubig, President of the STOA (Science and Technology Option Assessment Panel at the Research and Development Department of the European Parliament), Arnd Hoeveler, Head of the “Innovative tools, technologies and concepts health research” Unit at the Directorate Health of DG Research and Innovation at the European Commission, Patrizia Toia, EU parliamentarian, came together for the presentation along with Rino Rappuoli Chief Scientists of GSK Vaccines and President of the Sclavo Vaccines Association (SVA) and Donata Medaglini, from the University of Siena and vice-president of SVA, scientific coordinator of Aditec and Italian Parliamentarian Luigi Dallai and Rector of the University of Siena Francesco Frati.
Scientific coordinator Donata Medaglini said: “Aditec is new organization research paradigm which supports the dialogue between the most important public and private laboratories in Europe, creating a tool box for the development of vaccines in very short terms, in a sector where intervention rapidity is crucial. Also cost reduction has been considerable. The method used by Aditec is networking of technologies and experiences to rapidly succeed in identifying the best way to go. If the European Union will continue to support the project, we will make great technological advances for the vaccines of the future”.
Arnd Hoeveler, from the European commission said: “Aditec is an impressive project, truly interdisciplinary which has developed a culture of openness and collaborative work and which has delivered high impact results going clearly beyond the original scope of the project.”
By financing Aditec, under the European Commission VII Framework Programme (FP7) for Research and Technological Development, the European commission has developed a solid platform for the innovation of the vaccine research and development sector, with a significant social and economic impact. The project has been recently prolonged to 2017.
The project is coordinated by Sclavo Vaccines Association (SVA), a non-profit association specifically set up by the University of Siena and Azienda Ospedaliera Universitaria Senese as founding members, along with other 10 research institutions from 7 European countries, with the purpose of addressing the studies performed to support scientific research and discovery of new immunization technologies and development of vaccines also for low-income countries.